A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis

Abstract

Lafutidine has a high endoscopic healing rate and improves symptoms of heartburn in patients with mild reflux esophagitis. Lafutidine is considered a promising treatment option for mild reflux esophagitis.

Effectiveness and Tolerability of Different Recommended Doses of PPIs and H2RAs in GERD: Network Meta-Analysis and GRADE system

“…The most important and widely used therapeutic regimen is drug therapy, which includes treatment with proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H 2 RAs)91113. However, the use of pharmacological agents comes with the concern of tolerability141516, defined as discontinuation caused for any reason, including ineffectiveness, adverse effects and a lack of compliance. There is substantial evidence for the effectiveness and tolerability of pharmacological agents in the treatment of GERD141718192021.…”

Novel Upcoming Therapies

“…In a randomized, double-blind, placebo-controlled study that included 584 subjects with an endoscopic diagnosis of Los Angeles grades A and B EE, patients received lafutidine (20 mg once daily), famotidine (40 mg once daily), or placebo for 8 weeks. The authors demonstrated that lafutidine had an endoscopic healing rate of 71 % as compared with 61.4 and 9.7 %, in the famotidine and placebo groups, respectively [17]. In another study, 23 patients diagnosed with NERD (two or more heartburn episodes per week, a questionnaire for the diagnosis of reflux esophagitis score of 6 or above, and a negative upper endoscopy) underwent a 24-h pH test at baseline and again after 4 weeks of treatment with lafutidine (10 mg twice daily).…”

New and Future Drug Development for Gastroesophageal Reflux Disease

“…In a randomized, double-blind, placebo-controlled study that included 584 subjects with an endoscopic diagnosis of LA-A and LA-B EE, patients received either lafutidine (20 mg once daily), famotidine (40 mg once daily), or placebo for 8 weeks. The authors demonstrated that lafutidine had an endoscopic healing rate of 71% as compared with 61.4% and 9.7%, in the famotidine and placebo groups, respectively 23. In another study, 23 subjects with heartburn 2 or more times a week, a quality of life and utility evaluation survey technology (QUEST) score of 6 or above, and a negative upper endoscopy, underwent a 24-hour pH test at baseline and again after 4 weeks of treatment with lafutidine (10 mg twice daily).…”